Skip to main content

Table 2 Adverse Events (Grade 1 + 2; ≥ 2%)

From: Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma

Adverse Event

Number

Percent

Nausea

23

38

Fatigue

13

21

Emesis

10

16

Rash

9

15

Chills

6

10

Back Pain

5

8

Weight Loss

4

7

Weakness

4

7

Pruritis

4

7

Poor Appetite

4

7

Shortness of Breath

4

7

Pain At Tumor Site

3

5

Insomnia

3

5

Lethargy

3

5

Rib Pain

2

3

Fever

3

5

Ascites

2

3

Cellulitis

2

3

Diarrhea

2

3

Pedal Edema

2

3

Hypotension

1

2

Cough

1

2

Whole Body Rash

1

2

Neck Pain

1

2

Presyncope

1

2

Malaise

1

2

Fluid Retention

1

2

Poor Oral Intake

1

2

Head Sweats

1

2

Diffuse Body Aches

1

2

Erythema

1

2

Abdominal Pain

1

2

Gait Imbalance

1

2

Pleuritis

1

2

Jaundice

1

2

Constipation

1

2

Nipple Irritation

1

2

Xerostomia

1

2

Chest Thrombosis

1

2

Vitiligo

1

2

Visual Disturbance

1

2

Diplopia

1

2

Perioral Numbness

1

2

Pruritus in Eyes

1

2